Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment

Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is a liver manifestation of metabolic syndrome, with a histological spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH can evolve into progressive liver fibrosis and eventually lead t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chengyuan Liang, Juan Li, Bin Tian, Lei Tian, Yuzhi Liu, Jingyi Li, Liang Xin, Jun Wang, Chao Fu, Zhenfeng Shi, Juan Xia, Yiting Liang, Kun Wang
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Non-alcoholic steatohepatitis (NASH)
Non-alcoholic fatty liver disease (NAFLD)
Succinate–GPR91
Liver fibrosis
Hepatic stellate cells (HSCs)
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/42782507ca174da88ab367632b871d41
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares